Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(1):1–5. doi: 10.1038/bjc.1998.433

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.

M Raderer 1, A Kurtaran 1, M Hejna 1, F Vorbeck 1, P Angelberger 1, W Scheithauer 1, I Virgolini 1
PMCID: PMC2062941  PMID: 9662242

Abstract

Recent studies have shown that various gastrointestinal tumours express substantial amounts of vasoactive intestinal peptide (VIP) receptors. Based on these observations, we have developed a receptor scintigraphy using [123I]VIP as a radioligand. An initial series performed at our institution showed promising potential for visualization of various gastrointestinal adenocarcinomas by means of [123I]VIP. In this article, we now report the results obtained in 80 consecutive patients with colorectal adenocarcinoma. Eighty consecutive patients with histologically verified colorectal cancer underwent scanning by means of [123I]VIP (1 microg, approximately 150 MBq). Thirteen patients were free of tumour after complete resection of Dukes' C cancer, eight patients presented with primary and 14 with locally recurrent tumours but were free of metastases. Ten patients had locally recurrent disease and liver, lung or lymph node metastases. Disease confined to organ metastases (i.e. liver, lung or lymph nodes) was present in 35 patients. The size of the primary or recurrent tumours ranged between 3 and 6 cm, and the size of metastases was between 1 and 13 cm in diameter. Scan results were evaluated independently by two nuclear medicine physicians in a blinded way, and results were then compared with computerized tomography (CT)scans not older than 4 weeks. Seven out of eight primary (87%) and 21 out of 24 (82%) locally relapsing cancers were imaged with [123I]VIP. Negative VIP scans were obtained in all 13 patients in whom the cancers had been curatively resected. All patients with lymph node metastases showed positive VIP scans (four out of four), and positive scans were obtained in 25 out of 28 (89%) patients with liver metastases and in two out of three cases with lung metastases. In four patients with relapsing cancer, the VIP scan indicated the presence of disease before CT, and in two patients the diagnosis of scar tissue instead of a local recurrence of rectal cancer as suggested by CT could be established. We conclude that [123I]VIP receptor scanning is a sensitive method for radioimaging of colorectal cancer with the potential to provide valuable additional information to conventional radiological methods.

Full text

PDF
1

Images in this article

3Figure 1
on p.3
3Figure 2
on p.3
3Figure 3
on p.3

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boring C. C., Squires T. S., Tong T., Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 1994 Jan-Feb;44(1):7–26. doi: 10.3322/canjclin.44.1.7. [DOI] [PubMed] [Google Scholar]
  2. DeCosse J. J., Tsioulias G. J., Jacobson J. S. Colorectal cancer: detection, treatment, and rehabilitation. CA Cancer J Clin. 1994 Jan-Feb;44(1):27–42. doi: 10.3322/canjclin.44.1.27. [DOI] [PubMed] [Google Scholar]
  3. Patt Y. Z., Podoloff D. A., Curley S., Kasi L., Smith R., Bhadkamkar V., Charnsangavej C. Technetium 99m-labeled IMMU-4, a monoclonal antibody against carcinoembryonic antigen, for imaging of occult recurrent colorectal cancer in patients with rising serum carcinoembryonic antigen levels. J Clin Oncol. 1994 Mar;12(3):489–495. doi: 10.1200/JCO.1994.12.3.489. [DOI] [PubMed] [Google Scholar]
  4. Peltomäki P., Aaltonen L. A., Sistonen P., Pylkkänen L., Mecklin J. P., Järvinen H., Green J. S., Jass J. R., Weber J. L., Leach F. S. Genetic mapping of a locus predisposing to human colorectal cancer. Science. 1993 May 7;260(5109):810–812. doi: 10.1126/science.8484120. [DOI] [PubMed] [Google Scholar]
  5. Reubi J. C. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med. 1995 Oct;36(10):1846–1853. [PubMed] [Google Scholar]
  6. Rutgers E. J. Radio-immunotargeting in colorectal carcinoma. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1243–1247. doi: 10.1016/0959-8049(95)00143-7. [DOI] [PubMed] [Google Scholar]
  7. Scheithauer W., Rosen H., Kornek G. V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993 Mar 20;306(6880):752–755. doi: 10.1136/bmj.306.6880.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Schlag P., Lehner B., Strauss L. G., Georgi P., Herfarth C. Scar or recurrent rectal cancer. Positron emission tomography is more helpful for diagnosis than immunoscintigraphy. Arch Surg. 1989 Feb;124(2):197–200. doi: 10.1001/archsurg.1989.01410020067011. [DOI] [PubMed] [Google Scholar]
  9. Seidman H., Mushinski M. H., Gelb S. K., Silverberg E. Probabilities of eventually developing or dying of cancer--United States, 1985. CA Cancer J Clin. 1985 Jan-Feb;35(1):36–56. doi: 10.3322/canjclin.35.1.36. [DOI] [PubMed] [Google Scholar]
  10. Stevenson G. Radiology in the detection and prevention of colorectal cancer. Eur J Cancer. 1995 Jul-Aug;31A(7-8):1121–1126. doi: 10.1016/0959-8049(95)00230-g. [DOI] [PubMed] [Google Scholar]
  11. Virgolini I., Kurtaran A., Raderer M., Leimer M., Angelberger P., Havlik E., Li S., Scheithauer W., Niederle B., Valent P. Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med. 1995 Oct;36(10):1732–1739. [PubMed] [Google Scholar]
  12. Virgolini I., Yang Q., Li S., Angelberger P., Neuhold N., Niederle B., Scheithauer W., Valent P. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994 Feb 1;54(3):690–700. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES